Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in people with obesity or overweight and type 2 diabetes (T2D), while also improving glycaemic control in the phase 3 SYNCHRONIZE-2 trial. The trial met its co-primary endpoints, with 79.3% of patients receiving survodutide achieving at least 5% weight loss, compared […]
The post Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial appeared first on Pharmafile.